Curis Inc. ( (CRIS) ) has released its Q1 earnings. Here is a breakdown of the information Curis Inc. presented to its investors.
Curis Inc. is a biotechnology company specializing in the development of emavusertib, a small molecule IRAK4 inhibitor, primarily targeting oncology indications such as primary central nervous system lymphoma (PCNSL) and acute myeloid leukemia (AML).
In its first quarter 2025 business update, Curis Inc. announced the appointment of Dr. Ahmed Hamdy as Chief Medical Officer, alongside significant progress in its clinical programs and financial results. The company is advancing towards potential accelerated approval for emavusertib in PCNSL, with ongoing patient enrollment in the TakeAim Lymphoma study.
Key highlights from the report include successful meetings with the FDA and EMA regarding the TakeAim Lymphoma study’s potential for accelerated approval, and the granting of Orphan Drug Designation for emavusertib in PCNSL in both the U.S. and Europe. Financially, Curis reported a net loss of $10.6 million, an improvement from the previous year’s $11.9 million loss, and revenues of $2.4 million, primarily from royalties.
The company also completed a registered direct offering and private placement, raising approximately $8.8 million, which will support its operations into the fourth quarter of 2025. Curis’s cash position stood at $20.3 million as of March 31, 2025.
Looking ahead, Curis remains focused on advancing emavusertib through regulatory pathways and expanding its clinical applications. The management expresses optimism about the potential of emavusertib in combination therapies and its broader application in oncology, aiming to bring this novel treatment to patients globally.